| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2004 | CA2677430A1 Compositions comprising dietary fat complexer and methods for their use |
| 02/26/2004 | CA2497347A1 R(+)-2-amino-3-hydroxypropanoic acid derivatives with glycinergic action |
| 02/26/2004 | CA2496445A1 Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors |
| 02/26/2004 | CA2496048A1 Use of murine genomic regions identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 02/26/2004 | CA2496044A1 A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles |
| 02/26/2004 | CA2495956A1 Sulfonamides as potassium channel blockers |
| 02/26/2004 | CA2495588A1 Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof |
| 02/26/2004 | CA2495511A1 Use of and some novel imidazopyridines |
| 02/26/2004 | CA2495492A1 Novel use of benzothiazole derivatives |
| 02/26/2004 | CA2495452A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | CA2495435A1 Nutritional supplement for adolescents |
| 02/26/2004 | CA2495433A1 Synergistic combinations |
| 02/26/2004 | CA2495409A1 Diaryl compounds as monoamine reuptake inhibitors |
| 02/26/2004 | CA2495370A1 Partial and full agonists of a1 adenosine receptors |
| 02/26/2004 | CA2495345A1 Topical anhydrous and ethanol-free ascomycin compositions |
| 02/26/2004 | CA2495184A1 Thrombopoietin receptor activators and process for their production |
| 02/26/2004 | CA2495068A1 Use of nf-kappa b inhibitors for the treatment of mastitis |
| 02/26/2004 | CA2494847A1 Enos mutants useful for gene therapy |
| 02/26/2004 | CA2494811A1 Therapeutic use of fused bicyclic or tricyclic amino acids |
| 02/26/2004 | CA2494687A1 Agonism of the 5ht2a receptor for treatment of thermoregulatory dysfunction |
| 02/26/2004 | CA2494683A1 The use of resveratrol to regulate expression of apolipoprotein a1 |
| 02/26/2004 | CA2494546A1 Substituted glycine derivatives for use as medicaments |
| 02/26/2004 | CA2494147A1 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 02/26/2004 | CA2494132A1 Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes |
| 02/26/2004 | CA2493920A1 Biaryl diazabicycloalkane amides as nicotinic acetylcholine agonists |
| 02/26/2004 | CA2493753A1 Immunostimulatory nucleic acids |
| 02/26/2004 | CA2493748A1 Methods and compositions for treatment of macular and retinal disease |
| 02/26/2004 | CA2493246A1 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists |
| 02/26/2004 | CA2493245A1 Novel quinuclidine derivatives and their use |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391461A1 Bicyclic lactam inhibitors of interleukin-1-beta converting enzyme |
| 02/25/2004 | EP1391458A2 Novel method for producing 5-aryloxymethyl-2-oxazolidinones |
| 02/25/2004 | EP1391457A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors |
| 02/25/2004 | EP1391456A1 2-iminoimidazole derivative (2) |
| 02/25/2004 | EP1391453A1 Pyroglutamic acid salt of amlodipine |
| 02/25/2004 | EP1391451A1 2-iminopyrrolidine derivates |
| 02/25/2004 | EP1391278A1 Vehicle used to apply chemical compounds to wood |
| 02/25/2004 | EP1391221A1 A pharmaceutical preparation containing palladium complex compounds and the uses thereof for treating cancer and autoimmune disease |
| 02/25/2004 | EP1391213A1 Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| 02/25/2004 | EP1391211A1 Chondrogenesis promoters |
| 02/25/2004 | EP1391206A1 Pharmaceutical compositions comprising arsenic for the treatment of lymphoma |
| 02/25/2004 | EP1391205A1 Pharmaceutical composition with RNA as cofactor of hemostasis |
| 02/25/2004 | EP1391204A1 Nerve cell survival promoters containing cyclic phosphatidic acid derivative |
| 02/25/2004 | EP1391203A1 Antitumor agents |
| 02/25/2004 | EP1391202A1 Liquid drug preparations |
| 02/25/2004 | EP1391201A1 Medicinal compositions |
| 02/25/2004 | EP1391200A1 Drug preparations |
| 02/25/2004 | EP1391199A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| 02/25/2004 | EP1391198A1 Novel sphingolipid synthesis inhibitor |
| 02/25/2004 | EP1391197A1 Process for preparation of compositions with a high content in avarol and their use |
| 02/25/2004 | EP1391194A1 Preparation for hair and/or scalp |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390512A1 A method for transfection of rna using electrical pulses |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390507A2 Genes and proteins involved in the biosynthesis of enediyne ring structures |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390495A2 Immunostimulatory oligodeoxynucleic molecules |
| 02/25/2004 | EP1390494A2 Method for stabilising of nucleic acids |
| 02/25/2004 | EP1390493A1 Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof |
| 02/25/2004 | EP1390491A1 Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
| 02/25/2004 | EP1390478A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody |
| 02/25/2004 | EP1390468A2 Identification of essential genes of aspegillus fumigatus and methods of use |
| 02/25/2004 | EP1390400A2 Pharmaceutical use for secreted bacterial effector proteins |
| 02/25/2004 | EP1390392A1 Methods to inhibit viral replication |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |
| 02/25/2004 | EP1390384A2 Chromosome-based platforms |
| 02/25/2004 | EP1390383A1 Antisense permeation enhancers |
| 02/25/2004 | EP1390378A1 Pharmaceutically active uridine esters |
| 02/25/2004 | EP1390377A1 Crystal forms of azithromycin |
| 02/25/2004 | EP1390372A1 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor |
| 02/25/2004 | EP1390371A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors |
| 02/25/2004 | EP1390370A1 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 02/25/2004 | EP1390369A1 4-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidine derivatives |
| 02/25/2004 | EP1390368A1 Disubstituted 7,9-guaninium halides as telomerase inhibitors |
| 02/25/2004 | EP1390367A1 DIHYDROIMIDAZO 5,1-A]-$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE |
| 02/25/2004 | EP1390366A1 The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene |
| 02/25/2004 | EP1390365A1 Novel sulfonate substituted pyrazol pyridine dervivatives |
| 02/25/2004 | EP1390364A1 Aryl-8-azabicyclo 3.2.1]octanes for the treatment of depression |
| 02/25/2004 | EP1390363A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 02/25/2004 | EP1390362A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 02/25/2004 | EP1390361A2 Melanocortin receptor ligands |
| 02/25/2004 | EP1390360A1 Crystalline form of omeprazole |
| 02/25/2004 | EP1390358A1 Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent |
| 02/25/2004 | EP1390357A2 Anti-thrombotic compounds, production and use thereof as medicaments |
| 02/25/2004 | EP1390355A2 New crystal forms of lamotrigine and processes for their preparations |
| 02/25/2004 | EP1390353A1 Triazole-derived kinase inhibitors and uses thereof |
| 02/25/2004 | EP1390352A1 Pyrimidine derivatives |
| 02/25/2004 | EP1390351A1 Pyrimidine derivatives useful as selective cox-2 inhibitors |
| 02/25/2004 | EP1390350A1 Novel compounds |
| 02/25/2004 | EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 02/25/2004 | EP1390348A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors |
| 02/25/2004 | EP1390347A1 Pyrrolidine ester derivatives with oxytocin modulating activity |
| 02/25/2004 | EP1390345A1 Polythiourea lipid derivatives |
| 02/25/2004 | EP1390344A2 Organic compounds |
| 02/25/2004 | EP1390343A1 Novel retinoid derivatives and methods for producing said compounds and an anti-cancer pharmaceutical composition comprising said compounds |
| 02/25/2004 | EP1390081A2 Therapeutic and diagnostic compounds, compositions, and methods |
| 02/25/2004 | EP1390080A1 Azo compounds for type i phototherapy |
| 02/25/2004 | EP1390073A2 Compositions having enhanced pharmacokinetic characteristics |
| 02/25/2004 | EP1390072A2 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes |
| 02/25/2004 | EP1390070A1 Use of il-18 inhibitors for treating or preventing cns injuries |